Immune function tests for hazard identification: A paradigm shift in drug development

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 4, 2006, Pages 331-335

  Gore, Elizabeth R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CELL ADHESION MOLECULE; CYCLOSPORIN; KEYHOLE LIMPET HEMOCYANIN; METHADONE; MORPHINE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; SALMETEROL; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY RESPONSE; DISEASE SEVERITY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MECHANISM; DRUG REEXPOSURE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; EVALUATION; EVIDENCE BASED MEDICINE; FUNCTIONAL ASSESSMENT; HAZARD ASSESSMENT; HEALTH CARE ORGANIZATION; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOTOXICITY; INFECTION; METHODOLOGY; NONHUMAN; PARAMETER; PRACTICE GUIDELINE; PREDICTION; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SHEEP ERYTHROCYTE; SHORT SURVEY; T LYMPHOCYTE; TOXICOLOGY; UNCERTAINTY; VIRUS CULTURE;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; T-LYMPHOCYTES; TOXICITY TESTS;

OVIS ARIES;

EID: 33645705647     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_374.x     Document Type: Short Survey

References (42)

1. Alonzo N. C. B. M. Bayer Opiods, immunology and host defenses of intravenous drug abusers Infect. Dis Clin. N. Amer. 2002 16 553 569
2. Badger A. M. J. A. Handler C. A. Genell D. Herzyk E. Gore R. Polsky L. Webb P. Bugelski Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in candida-infected mice Int. J. Immunopharm. 1999 21 161 176
3. Basketter D. A. J. N. Bremmer P. Buckley M. E. Kammuller T. Kawabata I. Kimber S. E. Loveless S. Magda D. A. Stringer H. W. Vohr Pathology considerations for, and subsequent risk assessment of, chemicals identified as immunosuppressive in routine toxicology Food Chem. Toxicol. 1995 33 239 242
4. Cederbrandt K. M. Marcusson-Stahl F. Condevaux J. Descotes NK-cell activity in immunotoxicity drug evaluation Toxicology 2003 185 241 250
5. CPMP, Committee on Proprietary Medicinal Products Note for guidance on repeated-dose toxicity 2000 CPMP/SWP/1042/99,10:26 06/04/2006
6. Crevel R. W. R. J. A. Buckley J. A. Robinson I. J. Sanders Immunotoxicological assessment of cyclosporin A by conventional pathological techniques and immune function testing in the rat Human Exp. Toxicol. 1997 16 79 88
7. Dean J. H. A brief history of immunotoxicology and a review of the pharmaceutical guidelines Int. J. Toxicol. 2005 23 83 90
8. Dean J. H. J. R. Hincks B. Remandet Immunotoxicology assessment in the pharmaceutical industry Toxicol. Letters 1998 102&103 247 255
9. Dean J. H. M. I. Luster G. A. Boorman L. A. D. Lauer R. W. Leubke L. Lawson Selective immunosuppression resulting from exposure to the carcinogenic congener of benzopyrene in B6C3F1 mice Clin. Exp. Immunol. 1983 52 199 206
10. Descotes G. D. Pinard J.-F. Gallas E. Penacchio C. Blot C. Moreau Extension of the 4-week safety study for detecting immune system impairment appears not necessary: example of cyclosporin A in rats Toxicology 1996 112 245 256.
11. DeWaal E. J. J. W. van der Laan H. Van Loveren Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats Toxicology 1998 129 201 210
12. FDA Guidance for industry: immunotoxicology evaluation of investigational new drugs 2002
13. Gholizadeh Y. P. Courvalin Acquired and intrinsic glycopeptide resistance in enterococci Int. J. Antimicrob. Agents 2001 16 11 17
14. Gore E. R. J. Gower E. Kurali J.-L. Sui J. Bynum D. Ennulat D. Herzyk Primary antibody response to keyhole limpet hemocyanin in rat as a model for immunotoxicity evaluation Toxicology 2004 197 23 35
15. Hahm B. M. J. Trifilo E. I. Zuniga M. B. Oldstone Viruses evade the immune system through type I interferon mediated STAT2-dependent, but STAT1 independent, signaling Immunity 2005 22 247 257
16. Hastings K. L. C.-H. Ahn S. Y. Alam A. Aszalos Y. S. Choi J. J. Jessop J. L. Weaver Considerations in assessing the immunotoxic potential of drugs Drug Inf. J. 1997 31 1357 1361
17. Hastings K. L. Implications of the new FDA/CDER immunotoxicology guidance for drugs Int. Immunopharmacol. 2002 2 1613 1618
18. Herzyk D. J. Assessing immunotoxicity of pharmaceuticals: the need for enhanced testing Fund. Clin. Pharmacol. 2005 19 323 328
19. Herzyk D. J. E. R. Gore Adequate immunotoxicity testing in drug development Toxicol. Letters 2004 149 115 122
20. Hou J. E. O. Major Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host J. Neurovirol. 2000 2 Suppl. 2 S98 S100
21. ICICIS Group Investigators Report of validation study of direct immunotoxicity in the rat Toxicology 1998 125 183 201
22. Karchmer A. W. Nosocomial bloodstream infections: organisms, risk factors, and implications Clin. Infect. Dis. 2000 31 S139 S143
23. Kleinschmidt-DeMasters B. K. K. L. Tyler Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta 1a for multiple sclerosis New Engl. J. Med. 2005 353 369 374
24. Koralnik I. New insights into progressive multifocal leukoencephalopathy Curr. Opinion Neurol. 2004 17 365 370
25. Kuper C. F. J. H. Harleman H. B. Richter-Reichelm J.G. Vos Histopathology approaches to detect changes indicative of immunotoxicity Toxicol. Pathol. 2000 28 454 466
26. Ladics G. S. C. Smith K. Heaps G. S. Elliot T. W. Slone S. E. Loveless Possible incorporation of an immunotoxicological functional assay for assessing humoral immunity for hazard identification purposes in rats on standard toxicology study Toxicology 1995 96 225 238
27. Ladics G. C. Smith G. S. Elliot T. W. Slone S. E. Loveless Further evaluation of the incorporation of an immunotoxicological functional assay for assessing humoral immunity for hazard identification purposes in rats in a standard toxicology study Toxicology 1998 126 137 152
28. Langer-Gould A. S. W. Atlas A. W. Bollen D. Pelletier Progressive multifocal leukoencephalopathy in a patient treated with natulizumab New Engl. J. Med. 2005 353 375 381
29. Luster M. I. C. Portier D. G. Pait K. L. White Jr. C. Gennings A. E. Munson G. J. Rosenthal Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests Fund. Appl. Toxicol. 1992 18 200 210
30. Paccani S. R. M. Boncritiano C. T. Baldari Molecular mechanisms underlying suppression of lymphocyte responses by nonsteroidal anti-inflammatory drugs Cell. Mol. Life Sci. 2003 60 1071 1083
31. Pelligrino T. C. B. M. Bayer Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity require endogenous serotonin release Neuroimmunomodulation 2000 8 179 187
32. Polo C. J. L. Perez A. Mielnichuck C. G. Fedele J. Niubo A. Tenuorio Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children Clin. Microbiol. Infect. 2004 10 640 644
33. Putman E. J. W. van der Laan H. van Loveren Assessing immunotoxicity: guidelines Fund. Clin. Pharmacol. 2003 17 615 626
34. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus Infect. 2004 32 315 327
35. Ryle P. R. Justification for routine screening of pharmaceutical products in immune function tests: a review of the recommendations of Putman et al. 2003 Fundam. Clin. Pharmacol. 2005 19 317 322
36. Scheinfeld N. Adalimumab: a review of side effects Expert Opin. Drug Safety 2005 4 637 641
37. Smith H. W. C. J. Winstead K. K. Stank B. W. Halstead D. Wierda A predictive F344 rat immunotoxicology model: cellular parameters combined with humoral response to NP-CyG and KLH Toxicology 2003 194 129 145
38. Snodin D. J. Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development? Reg. Toxicol. Pharmacol. 2004 40 336 355
39. Ulrich P. G. Paul E. Perented A. Mahl D. Roman Validation of immune function testing during a 4-week oral toxicity study with FK506 Toxicol. Letters 2004 149 123 131
40. Van Assche G. M. Van Ranst R. Sciot B. Dubois S. Vermeire M. Noman J. Verbeeck K. Geboes W. Robberecht P. Rutgeerts Progressive multifocal encephalopathy after natalizumab therapy for Chrohn's disease New Engl. J. Med. 2005 353 362 368
41. Van der Laan J. W. H. van Loveren Immune function testing of human pharmaceuticals: regulatory overshoot? Expert Opinion Drug Safety 2005 4 1 3
42. Vos J. G. H. van Loveren Experimental studies on immunosuppression? How do they predict for man? Toxicology 1998 129 13 26